{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"FibroBiologics, Inc."},"Symbol":{"label":"Symbol","value":"FBLG"},"Address":{"label":"Address","value":"455 EAST MEDICAL CENTER BOULEVARD,SUITE 300,HOUSTON, TEXAS, Texas, 77598, United States"},"Phone":{"label":"Phone","value":"281 671 5150"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"FibroBiologics, Inc. operates as a clinical-stage cell therapy company that focuses on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs. The company develops CybroCell for degenerative disc disease; CYMS101 to treat multiple sclerosis; and CYWC628 for treating wound healing. Its early-stage research programs include CYTER915 which is designed to regenerate or reinvigorate production of the thymus and/or spleen; and TCB190 for the treatment of cancers. The company was incorporated in 2021 and is based in Houston, Texas. FibroBiologics, Inc. operates as a subsidiary of Spinalcyte Llc."},"CompanyUrl":{"label":"Company Url","value":"https://www.fibrobiologics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Hamid Khoja","title":"Chief Scientific Officer"},{"name":"Peter O'Heeron","title":"Chairman & Chief Executive Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}